And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is quite modest. We plan to catch up on our reading, promenade with the official mascot and check in on the Pharmalot ancestors. And what about you? This is a fine time to hunt for apples and pumpkins. You could drop off your ballot or boost the economy by purchasing a few sweaters. Or make time to touch base with someone feeling isolated. Well, whatever you do, have a grand time. But be safe, wear a mask. Enjoy, and see you on Tuesday, due to a holiday break. …

President Trump and White House chief of staff Mark Meadows have urged Food and Drug Administration commissioner Stephen Hahn to accelerate agency reviews of antibody cocktails from Regeneron Pharmaceuticals (REGN) and Eli Lilly (LLY) for treating Covid-19, The Washington Post reports. Both drug makers have sought emergency use authorization from the FDA. Trump said the administration intends to make both treatments free for patients suffering from the virus, especially seniors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy